Results 61 to 70 of about 48,562 (198)

Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature

Pulmonary Circulation, 2019
Background Pulmonary arterial hypertension consists in an increase of mean pulmonary arterial pressure (PAPm ≥ 25 mmHg), and may lead to right ventricular failure.
A. Trombetta, S. Ghirardo, S. Pastore, A. Tesser, E. Piscianz, A. Tommasini, M. Bobbo, A. Taddio   +7 more
doaj   +1 more source

Janus Kinase Inhibitors in Dermatology

Indian Journal of Drugs in Dermatology, 2019
Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts. This review throws light on JAK inhibitors and their role
openaire   +1 more source

Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis.

PURPOSE Janus kinase (JAK) inhibitors have recently been used to treat patients with biologic refractory noninfectious uveitis (NIU). This narrative review updates the current evidence relevant for their application in patients with refractory NIU.
Garweg, Justus G, Straessle, Kim A
core   +1 more source

An atypical mycobacterial infection while on Janus kinase inhibitor therapy [PDF]

Janus kinase inhibitors are immunomodulatory drugs increasingly used to treat a broad range of inflammatory dermatologic conditions. Although effective, they carry a risk of serious adverse effects, including opportunistic infections.
Rogge, Megan N, Black, T Austin, Aboul-Fettouh, Nader, Valek, Stephanie A   +3 more
core   +1 more source

Assessing cardiovascular risk in rheumatoid arthritis patients on Janus kinase inhibitors: real-world data from the European Alliance of Associations for Rheumatology-adapted CUORE risk algorithm

Janus kinase inhibitors (JAKi) are effective treatments for rheumatoid arthritis (RA), but growing evidence raises cardiovascular (CV) safety concerns. Given the elevated baseline CV risk in RA, appropriate risk stratification is essential.
Mario Cascone, Francesco Caso, Nicoletta Bertolini, Alfonso Oriente, Luisa Costa, Rosario Peluso, Francesca Foglia, Marco Tasso, Antonio Del Puente   +8 more
core   +1 more source

Janus kinase inhibitors in dermatology: Part I. A comprehensive review

, 2021
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is utilized by many proinflammatory molecules to mediate downstream effects and activate gene transcription.
Chapman, Stephanie, Kwa, Michael, Lim, Henry W, Stein Gold, Linda F   +3 more
core  

Role of janus kinase inhibitors in the treatment of alopecia areata

, 2018
Korn Triyangkulsri, Poonkiat Suchonwanit Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Abstract: Alopecia areata (AA) is a common hair loss disorder worldwide with ...
Suchonwanit P, Triyangkulsri K
core  

Inhibitors of the interferon response enhance virus replication in vitro.

, 2014
This work was supported by the University of St Andrews (CSA, CES) and the Wellcome Trust (grant 087751/A/08/Z) (RER).Virus replication efficiency is influenced by two conflicting factors, kinetics of the cellular interferon (IFN) response and induction ...
Richard E. Randall, Catherine S. Adamson, Catherine S Adamson, Claire E Stewart, Richard E Randall, Adamson, Catherine S, Stewart, Claire Emma, Randall, Richard Edward, Claire E. Stewart   +8 more
core   +1 more source

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement

, 2020
Objectives: Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review ...
Nash, P, Trauner, M, Dörner, T, Stoffer-Marx, M, Takeuchi, T, De Wit, M, Van Der Heijde, D, Geissler, K, Fleischmann, RM, Pope, JE, Dougados, M, Kerschbaumer, A, McInnes, I, Winthrop, KL, et al.   +14 more
core   +1 more source

A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib

BMC Infectious Diseases, 2019
Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj   +1 more source